169 related articles for article (PubMed ID: 34921111)
1. Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation.
Guo X; Xu L; Velazquez H; Chen TM; Williams RM; Heller DA; Burtness B; Safirstein R; Desir GV
J Am Soc Nephrol; 2022 Feb; 33(2):342-356. PubMed ID: 34921111
[TBL] [Abstract][Full Text] [Related]
2. Effects of repeated increasing doses of cisplatin as models of acute kidney injury and chronic kidney disease in rats.
Al Za'abi M; Al Salam S; Al Suleimani Y; Ashique M; Manoj P; Nemmar A; Ali BH
Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):249-259. PubMed ID: 32936352
[TBL] [Abstract][Full Text] [Related]
3. RENALASE: DISCOVERY, BIOLOGY, AND THERAPEUTIC APPLICATIONS.
Desir GV
Trans Am Clin Climatol Assoc; 2022; 132():117-125. PubMed ID: 36196172
[TBL] [Abstract][Full Text] [Related]
4. Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease.
Landau SI; Guo X; Velazquez H; Torres R; Olson E; Garcia-Milian R; Moeckel GW; Desir GV; Safirstein R
Kidney Int; 2019 Apr; 95(4):797-814. PubMed ID: 30904067
[TBL] [Abstract][Full Text] [Related]
5. Renalase attenuates mitochondrial fission in cisplatin-induced acute kidney injury via modulating sirtuin-3.
Huang Z; Li Q; Yuan Y; Zhang C; Wu L; Liu X; Cao W; Guo H; Duan S; Xu X; Zhang B; Xing C
Life Sci; 2019 Apr; 222():78-87. PubMed ID: 30797821
[TBL] [Abstract][Full Text] [Related]
6. Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.
McMahon KR; Harel-Sterling M; Pizzi M; Huynh L; Hessey E; Zappitelli M
Pediatr Nephrol; 2018 Dec; 33(12):2311-2320. PubMed ID: 30218190
[TBL] [Abstract][Full Text] [Related]
7. Renalase protects against ischemic AKI.
Lee HT; Kim JY; Kim M; Wang P; Tang L; Baroni S; D'Agati VD; Desir GV
J Am Soc Nephrol; 2013 Feb; 24(3):445-55. PubMed ID: 23393318
[TBL] [Abstract][Full Text] [Related]
8. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors.
Sato K; Watanabe S; Ohtsubo A; Shoji S; Ishikawa D; Tanaka T; Nozaki K; Kondo R; Okajima M; Miura S; Tanaka J; Sakagami T; Koya T; Kagamu H; Yoshizawa H; Narita I
BMC Cancer; 2016 Mar; 16():222. PubMed ID: 26979596
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin nephrotoxicity as a model of chronic kidney disease.
Shi M; McMillan KL; Wu J; Gillings N; Flores B; Moe OW; Hu MC
Lab Invest; 2018 Aug; 98(8):1105-1121. PubMed ID: 29858580
[TBL] [Abstract][Full Text] [Related]
10. Renalase prevents AKI independent of amine oxidase activity.
Wang L; Velazquez H; Moeckel G; Chang J; Ham A; Lee HT; Safirstein R; Desir GV
J Am Soc Nephrol; 2014 Jun; 25(6):1226-35. PubMed ID: 24511138
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial modulation by Epigallocatechin 3-Gallate ameliorates cisplatin induced renal injury through decreasing oxidative/nitrative stress, inflammation and NF-kB in mice.
Pan H; Chen J; Shen K; Wang X; Wang P; Fu G; Meng H; Wang Y; Jin B
PLoS One; 2015; 10(4):e0124775. PubMed ID: 25875356
[TBL] [Abstract][Full Text] [Related]
12. Chronic effects of repeated low-dose cisplatin treatment in mouse kidneys and renal tubular cells.
Fu Y; Cai J; Li F; Liu Z; Shu S; Wang Y; Liu Y; Tang C; Dong Z
Am J Physiol Renal Physiol; 2019 Dec; 317(6):F1582-F1592. PubMed ID: 31532246
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice.
Santana AC; Degaspari S; Catanozi S; Dellê H; de Sá Lima L; Silva C; Blanco P; Solez K; Scavone C; Noronha IL
Nephrol Dial Transplant; 2013 May; 28(5):1140-9. PubMed ID: 23345625
[TBL] [Abstract][Full Text] [Related]
14. Pregnane X receptor (PXR) protects against cisplatin-induced acute kidney injury in mice.
Luan Z; Wei Y; Huo X; Sun X; Zhang C; Ming W; Luo Z; Du C; Li Y; Xu H; Lu H; Zheng F; Guan Y; Zhang X
Biochim Biophys Acta Mol Basis Dis; 2021 Mar; 1867(3):165996. PubMed ID: 33127475
[TBL] [Abstract][Full Text] [Related]
15. Cardiac-specific renalase overexpression alleviates CKD-induced pathological cardiac remodeling in mice.
Wang Y; Bai L; Wen J; Zhang F; Gu S; Wang F; Yin J; Wang N
Front Cardiovasc Med; 2022; 9():1061146. PubMed ID: 36588579
[TBL] [Abstract][Full Text] [Related]
16. Cumulative DNA damage by repeated low-dose cisplatin injection promotes the transition of acute to chronic kidney injury in mice.
Yamashita N; Nakai K; Nakata T; Nakamura I; Kirita Y; Matoba S; Humphreys BD; Tamagaki K; Kusaba T
Sci Rep; 2021 Oct; 11(1):20920. PubMed ID: 34686727
[TBL] [Abstract][Full Text] [Related]
17. Rs10887800 renalase gene polymorphism influences the level of circulating renalase in patients undergoing hemodialysis but not in healthy controls.
Stec A
BMC Nephrol; 2017 Apr; 18(1):118. PubMed ID: 28372594
[TBL] [Abstract][Full Text] [Related]
18. Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a STAT3-Mediated Mechanism.
Hollander L; Guo X; Velazquez H; Chang J; Safirstein R; Kluger H; Cha C; Desir GV
Cancer Res; 2016 Jul; 76(13):3884-94. PubMed ID: 27197188
[TBL] [Abstract][Full Text] [Related]
19. Galectin 3 inhibition attenuates renal injury progression in cisplatin-induced nephrotoxicity.
Li HY; Yang S; Li JC; Feng JX
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30455396
[TBL] [Abstract][Full Text] [Related]
20. Iron sucrose ('RBT-3') activates the hepatic and renal HAMP1 gene, evoking renal hepcidin loading and resistance to cisplatin nephrotoxicity.
Zager RA; Johnson ACM; Therapeutics R
Nephrol Dial Transplant; 2021 Feb; 36(3):465-474. PubMed ID: 33547792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
